Skip to main content

Table 2 Initial meropenem pharmacokinetic parameters

From: Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients

Patient N° V ss V ss/weight V ss2/V ss AUC Cl T1/2 Peak Trough T > 2 mg/L T > 4 mg/L T > 8 mg/L
  L L/Kg % L/mg.h mL/min h mg/L mg/L 100% 90% 70%
1 19.6 0.25 50.6% 157.1 106.7 2.9 63.3 3.0 100% 100% 100%
2 NA NA NA 264.7 63.3 1.5 NA 11.9 100% 100% 100%
3 13.6 0.21 56.3% 253.3 65 2.6 94.1 8.6 100% 100% 85%
4 13.6 0.17 78.4% 160.1 103.3 1.7 102.3 4.8 100% 85% 50%
5 13.4 0.16 51.8% 129.2 128.3 1.3 80.1 2.7 100% 90% 65%
6 32.7 0.42 93.7% 134.9 123.3 3.4 52.0 3.0 100% 100% 100%
7 18.6 0.23 73.6% 479.2 35 6.4 84.7 NA 100% 100% 100%
8 14.9 0.25 88.7% 465.9 35 5.0 91.3 NA 100% 100% 75%
9 6.7 0.07 90.4% 232.5 71.7 1.4 192.5 4.4 100% 75% 50%
10 13.0 0.16 58.4% 139.5 120 1.5 85.1 2.4 100% 75% 50%
11 20.9 0.30 68,6% 107.3 155 1.9 58.6 2.9 100% 100% 100%
12 13.6 0.18 79.2% 304.2 55 3.5 119.8 8.6 75% 50% 35%
13 17.1 0.27 34.9% 81.4 205 1.3 56.9 0.6 100% 100% 55%
14 22.5 0.28 53.1% 120.7 138.3 2.1 48.4 4.1 100% 100% 100%
15 13.0 0.13 68.6% 315.3 53.3 3.3 124.2 12.5 100% 90% 70%
Geometric mean 15.7 0.2 63.1% 190.2 73.3 2.3 85.9 3.8 100% 100% 100%
95% CI 12.7-19.4 0.15-0.27 52.7-75.5% 138.4-261.4 45-120 1.8-3.1 69.2-106.6 2.3-6.2    
  1. V ss – Volume of distribution at steady state; V ss2 - Volume of distribution at steady state (peripheral compartment); AUC – Area under the concentration-time curve; Cl – Meropenem clearance; T1/2 – Half life; NA- Data not available; IQR – Interquartile range; 95% CI - 95% confidence interval of the mean; T > - Percentage of time that meropenem concentration was above 2, 4 and 8 mgL.